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j ourna l homepage: www.eb iomed ic ine.comEditorialFlavivirus vaccines: Innovate, invest, implementWorld Immunization Week 2016 is April 24–30. Coincidentally, on
April 4 the Philippines launched a dengue immunization program
targeting more than 1 million schoolchildren using the world's ﬁrst
dengue vaccine, CYD-TDV (Dengvaxia®). It took more than 20 years of
research and development, including two Phase 3 clinical trials involving
over 35,000 participants aged 2–16 years, for this new vaccine to reach
approval—ﬁrst in Mexico, the Philippines and Brazil in December 2015,
then El Salvador in February 2016, with several other countries in the
process of regulatory review.
Over the past ﬁve decades, from being present in only a few coun-
tries, dengue is now endemic in more than 100 tropical and subtropical
countries and is a major public health problem in Asia, Latin America
and Africa. TheWorldHealth Organization (WHO) reports an estimated
390million dengue infections every year, with 500,000 hospitalizations
and 25,000 deaths. The causative agent, dengue virus, exists in four
serotypes. Recovery from infection with one serotype usually results
in lifelong immunity against that serotype, but not the others, while
subsequent infections with other serotypes can lead to severe dengue,
including the life-threatening dengue hemorrhagic fever. One possible
explanation is antibody-dependent enhancement (ADE) when non-
neutralizing antiviral antibodies help the virus gain entry into host
cells and increase viral infectivity, although other immune components
may also play a role. It is thus crucial for a dengue vaccine to induce
immunity against all four serotypes concurrently.
CYD-TDV is a live attenuated, tetravalent, chimeric vaccine that is
built on the backbone of the yellow fever 17D vaccine strain, which
has been commercially available since the 1950s. Using DNA recombi-
nation technology, the pre-membrane (prM) and envelope (E) genes
of 17D strain are replacedwith those from each of the four dengue sero-
types. In clinical trials, CYD-TDV was capable of inducing immunity
against all four dengue serotypes, and resulted in 80% reduction in
hospitalization and 90% reduction in severe dengue.
Dengue virus and yellow fever virus both belong to the genus
Flavivirus that also includes West Nile virus (WNV) and Zika virus
(ZIKV)—all of which can be transmitted by the mosquito Aedes aegypti
that thrives in tropical and subtropical climates worldwide. There is
only one ZIKV serotype, but unlike dengue, less is known about ZIKV
pathogenesis. Because ZIKV infections generally produce mild
inﬂuenza-like symptoms, the disease has been neglected for decades
until the recent major outbreaks when the virus was suspected of
being linked to serious neurological disorders, including Guillain–
Barré syndrome (GBS) and fetal microcephaly. The current ZIKV out-
break started in 2015 in Brazil, spread quickly to several countries in
Latin America, and is predicted to reach most of the Americas later in
2016. The WHO declared a global emergency in February 2016, and
several research groups have rushed into developing a Zika vaccine.http://dx.doi.org/10.1016/j.ebiom.2016.04.006
2352-3964/© 2016 The Author. Published by Elsevier B.V. This is an open access article underDue to the lack of ZIKV basic research, there are many unanswered
questions when it comes to developing Zika vaccines. Which animal
models are suitable to test such vaccines? Which immune surrogate
markers can be used to assess vaccine efﬁcacy? Can anti-ZIKV antibod-
ies result in ADE and facilitate cellular infectivity of other ﬂaviviruses, or
increase the chance of developing autoimmune GBS? If a vaccine
candidate becomes available too late after the current ZIKV epidemic
has subsided, how can we measure its effectiveness in the population?
Fortunately previous groundwork on other ﬂaviviruses, in particular
WNV, could provide useful insights and directions in ZIKV research. The
US National Institutes of Health (NIH) has previously developed aWNV
vaccine candidate, which is a plasmid DNA expressing PrM/E glycopro-
tein of WNV strain NY99. NIH researchers now use the same plasmid
vector butwith prM/E genes fromZIKV to create a newZika vaccine can-
didate. Human clinical trials of this DNA vaccine are scheduled to start in
late summer 2016—one of the fastest timelines in vaccine research.
Despite the knowledge gap about ZIKV neuropathogenesis and the
imminent spread of the virus into the US in summer 2016, President
Obama's request of $1.9 billion in emergency response funds is being
locked in a congressional debate. In the UK, the government has trebled
its ZIKV research funding to £3 million, with a further £1 million from
the Wellcome Trust. Funding for vaccine research is vital and requires
all stakeholders, from governmental and private funding bodies to the
pharmaceutical industry, to understand medical needs and prioritize
research directions.
Beyond science, funding and regulatory approval, a vaccine cannot
succeed without public acceptance and engagement. Cultural and
religious barriers need to be overcome, and scientiﬁcally clear commu-
nication about the vaccine's beneﬁts and potential side effects is crucial.
In resource-limited countries wheremosquito-transmitted ﬂaviviral in-
fections are prevalent, logistical issues to ensure vaccines reach remote
areas can present another hurdle. Bridging this gap in vaccine
deployment is essential to the success of an immunization campaign
and safeguards the protection of the community from infections.
The theme of this year's World Immunization Week is “Closing the
Immunization Gap”. While the recent approval of CYD-TDV is
welcomed news, much more work remains to be done before the
vaccine is fully integrated into health care systems and a reduction in
global dengue burden can be demonstrated. Failure to close the gaps
in scientiﬁc knowledge, funding and heath care practice could jeopar-
dize our position in the ﬁghts against ﬂaviviral diseases like dengue
and Zika, as well as other infectious diseases.
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